Iovance Biotherapeutics
An intern will gain hands-on experience in the biotech industry, working with cutting-edge equipment and technologies to evaluate TIL expansion and cell density impact on TIL growth through ex-vivo assays and culture methods.
Headquarters
San Carlos, California, United States
Company Size
501-1000 employees
Founded
2007
Iovance Biotherapeutics is a clinical-stage biopharmaceutical company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Its lead product Amtagvi (lifileucel) is being investigated in multiple clinical trials, with manufacturing conducted at the Iovance Cell Therapy Center in Philadelphia, PA, and collaborations with academic and industry partners to advance next-generation TIL platforms.
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook
7 hours ago
A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum
3 days ago
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036
1 week ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Iovance Biotherapeutics.
Iovance Biotherapeutics didn’t post a salary, so this is our estimate from similar listings.
Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years
1 week ago